Full-Time
Health, Safety & Environment Manager
Manufacturing
Posted on 6/20/2026
Alcon
10,001+ employees
Eye care products and vision solutions
No salary listed
Melbourne VIC, Australia
In Person
Applicants must have the right to live and work in Australia; no visa sponsorship or relocation provided.
 Legal & Compliance (1) |
|---|
- Bachelor’s degree in Occupational Health & Safety, Environmental Science, or a related field.
- Postgraduate qualifications desirable.
- Minimum 5 years’ experience in a similar HSE management role, preferably within the healthcare, pharmaceutical, or manufacturing sectors.
- Comprehensive knowledge of Australian HSE legislation and standards.
- Strong leadership, communication, and interpersonal skills.
- Proven ability to influence and drive cultural change regarding safety and environment.
- Professional certifications (e.g., Cert IV in Work Health and Safety, Lead Auditor) are highly regarded.
- Applicants must have the right to live and work in Australia. No visa sponsorship nor relocation will be provided for this role.
- Lead the development, implementation, and continuous improvement of HSE policies, procedures, and initiatives.
- Ensure compliance with all relevant legislation, codes of practice, and industry standards relating to workplace health, safety, and environment.
- Conduct regular risk assessments, audits, and inspections to identify hazards and implement corrective actions as required.
- Provide expert advice and support to management and staff on HSE matters, fostering a proactive safety culture.
- Coordinate incident investigations, root cause analysis, and reporting, ensuring lessons learned are shared and corrective actions completed.
- Develop and deliver HSE training programs for employees at all levels.
- Monitor and report on HSE performance metrics, preparing regular reports for senior leadership.
- Manage relationships with external regulatory bodies and participate in industry forums as required.
- Promote environmental sustainability initiatives and ensure compliance with environmental regulations.
- Postgraduate qualifications desirable.
- Professional certifications (e.g., Cert IV in Work Health and Safety, Lead Auditor) are highly regarded.
Alcon provides eye care products and vision solutions to improve how people see. It develops and manufactures devices and consumables for eye health, including cataract surgery equipment and intraocular lenses, retinal health therapies, and contact lenses, distributed through eye care professionals, hospitals, and consumers. The products work by supporting eye surgery, protecting and restoring vision, or correcting vision with lens-based options, backed by research and development and a global distribution network. Alcon differentiates itself with a broad, end-to-end portfolio across the eye care continuum, a strong emphasis on research and development, strategic partnerships with healthcare providers, and a commitment to diversity and inclusion. Its goal is to enhance vision and quality of life by delivering reliable, high-quality eye care solutions and advancing the science of eye health.
Company Size
10,001+
Company Stage
IPO
Headquarters
Geneva, Switzerland
Founded
1945
Your Connections
People at Alcon who can refer or advise you
Simplify's Take
What believers are saying
- UNITY CS and VCS strengthen Alcon's premium cataract surgery franchise.[3]
- Clareon TruPlus extends the Clareon portfolio with enhanced intermediate vision.[3]
- ARVO Eye Pitch and VisionX widen Alcon's external innovation pipeline.[3]
What critics are saying
- Competition from Johnson & Johnson, Bausch + Lomb, and Carl Zeiss Meditec intensifies.[4]
- Alcon's U.S. complaint channel underscores meaningful product-liability exposure in surgery-critical devices.[5]
- Execution on complex R&D and global commercialization requires sustained capital and operational discipline.[1][3]
What makes Alcon unique
- Alcon is the world's largest eye care device company, spanning Surgical and Vision Care.[1]
- Its R&D engine includes 2,100 associates and multiple partnership channels.[3]
- The company sells broad ophthalmic offerings across 140-plus countries through global manufacturing.[1]
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical, dental, & vision coverage
HSA Medical Plan
PTO
Paid Parental leave
401k
Retirement Plan Company Contribution
Low payroll deductions
Tuition Reimbursement Program
Annual Bonus
Free Family Contact Lens Program
12 Company Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 8%1 year growth
↑ 8%2 year growth
↑ 8%DKSH and Long Chau join forces to bring dry Eye Disease Screening to Vietnamese communities nationwide. DKSH together with Alcon and Topcon Healthcare supports FPT Long Chau Pharmacy's nationwide dry eye awareness initiative by sponsoring advanced diagnostic equipment and bringing clinically proven eye care solutions to communities across all three regions of Vietnam. Ho Chi Minh City, Vietnam, 15 June 2026 - DKSH Healthcare, an integrated end-to-end healthcare commercialization platform, is proud to support the "Dry Eye Disease Screening Program" a community health initiative launched by FPT Long Chau Pharmacy chain in Vietnam. Together with Alcon Vietnam and leveraging Topcon Healthcare's advanced diagnostic technology, the program will be activated across selected Long Chau pharmacy locations nationwide, spanning all three regions of Vietnam. Dry eye disease is a growing public health concern in Vietnam but often remains widely underdiagnosed as many consumers attribute symptoms, such as eye irritation, fatigue, and blurred vision to temporary discomfort. The program addresses this gap by offering complimentary screenings and professional consultations at participating Long Chau locations, supported by Topcon Healthcare's MYAH diagnostic device alongside Alcon's Systane range as a clinically validated dry eye management solution in combination with DKSH's sponsoring. As the exclusive distributor of Topcon Healthcare's ophthalmic portfolio in Vietnam and a distribution partner for Alcon's consumer eye care products, DKSH plays a uniquely integrated role in the program, bridging healthcare innovation with real-world delivery, and enabling the infrastructure that allows community-level initiatives like this to take place at scale. This reflects DKSH's broader approach to healthcare partnerships in Vietnam. Through its integrated commercialization platform, DKSH bring innovative healthcare solutions to reach patients reliably, compliantly, and sustainably, translating scale, local expertise, and execution discipline into tangible patient outcomes and advancing the commitment to Healthcare for All. Ta Minh Cuong, General Manager, Business Unit Healthcare, DKSH Vietnam shared: "This program is a strong example of what becomes possible when distribution expertise, innovative technology, and trusted healthcare brands come together around a shared purpose. By pairing Topcon Healthcare's diagnostic capabilities with Alcon's Systane, DKSH is proud to go beyond logistics, enabling access to high-quality, high-standard technical services and evidence-based eye care for Vietnamese consumers, whether through our distribution network or through on-the-ground initiatives like this one." The program is a tangible expression of DKSH's commitment to Healthcare for All: simplifying complexity, strengthening local healthcare ecosystems, and ensuring that quality solutions reach patients and consumers reliably, across every region of Vietnam. About FPT Long Chau FPT Long Chau Pharmacy is one of Vietnam's leading pharmaceutical retail chains, operating under FPT Digital Retail JSC - a member of FPT Group. With over 2,678 outlets nationwide as of end-2025, Long Chau offers a comprehensive range of prescription and over-the-counter medicines, functional foods, medical devices, cosmeceuticals, and everyday health and consumer products. Backed by a nationwide distribution network and a team of professional pharmacists, Long Chau is committed to delivering quality, reliability, and care to customers across every region of Vietnam. www.nhathuoclongchau.com.vn About DKSH For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific, Europe, and North America across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution and logistics as well as after-sales services, following its purpose of enriching people's lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales of CHF 11.1 billion in 2025. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products and medical devices. With around 7,580 specialists, the Business Unit generated net sales of CHF 5.8 billion in 2025. www.dksh.com/hec
Alcon plans expansion in Right to Work West Virginia. Alcon is planning to expand soon in Right to Work Lesage, West Virginia. In order to accomplish this, the eye care company is investing a total of $81 million in the project. They will also create 75 new jobs! From Area Development Magazine: "We're super excited we can expand and bring new products. [...] This investment opens the door for future growth and continued expansion of our operations in the region." [...] "For decades, Alcon has shown that a global leader can find great success right here in the Mountain State. [...] This expansion demonstrates that West Virginia isn't just a place to do business, but that it's one of the best places in the world for a global leader to thrive." AREA DEVELOPMENT MAGAZINE
Alcon and ARVO continue partnership to champion innovation at 2026 live Eye Pitch event. April 29, 2026 Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced its continued collaboration with the Association for Research in Vision and Ophthalmology (ARVO) and support of its live Eye Pitch event, taking place at this year's ARVO Annual Meeting in Denver, Colorado, on Tuesday, May 5, 2026. The pitch contest invites ARVO members to present their innovative research, drug or device proposals to a panel of judges from ARVO and the Alcon Seed Fund, an innovation acceleration platform that identifies and invests in early- and mid-stage disruptive innovations within the ophthalmic field. "Looking at future innovation is critical to meeting the evolving needs of our customers and patients worldwide as we aim to advance the standard of eye care," said Franck Leveiller, SVP, Global Research and Development and Chief Scientific Officer, Alcon. "Eye Pitch underscores our dedication to discovering and championing promising early-stage ophthalmic solutions that have the potential to impact clinical practice. Our collaboration with ARVO brings together a dynamic community of researchers, clinicians and entrepreneurs who are shaping the future of vision science. The creativity and scientific rigor showcased through this program reinforce our optimism about what lies ahead - and our commitment to helping translate bold ideas into transformative care." Eye Pitch, hosted by ARVO and supported by Alcon, is a live competitive program held during the ARVO Annual Meeting that spotlights promising early- to mid-stage innovations in eye and vision research. ARVO members developing new treatments, devices, diagnostics and technologies submitted proposals for review by an expert panel, with finalists invited to deliver a five-minute pitch and participate in a live Q&A session. Finalists receive structured mentorship, and winners are awarded cash prizes. The overall winner is also invited to enter the Alcon Seed Fund diligence process for potential investment of up to $1 million to help advance breakthrough ophthalmic innovations aligned with Alcon's strategic priorities. Interest in the program continues to grow, with an increase of 43% from last year. Selected finalists will present on Tuesday, May 5, 2026, from 6:30 to 8:15 p.m. MT, followed by a networking reception. "Being selected for Eye Pitch last year was a meaningful milestone for our team," said Jonathan Labriola, PhD, Director of Operations at Synakis. "The mentorship helped us sharpen our scientific story and commercial strategy, and winning the competition brought valuable visibility to Synakis and reinforced the potential of our work. Connecting with leaders across vision science at ARVO made the experience especially rewarding." In addition to Eye Pitch, Alcon will also announce VisionX at ARVO 2026, which is a new global open innovation initiative of the Alcon Seed Fund designed to bring cross-disciplinary innovation into the industry. VisionX was created to identify breakthrough ideas emerging outside traditional ophthalmology including fields such as artificial intelligence, photonics, advanced materials, robotics, and computational imaging - and connect them to some of the most important challenges in vision science. By engaging researchers, engineers and entrepreneurs whose work may not currently focus on the eye, VisionX creates a structured pathway for early discovery, evaluation and potential advancement of novel technologies. In addition to Eye Pitch and VisionX, Alcon will also support the Alcon Research Institute (ARI), which will host the annual Steven M. Podos Colloquium on Saturday, May 2, at 5:30 p.m. MT at the Hyatt Regency Denver at the Colorado Convention Center. The event will feature leading experts, including Dr. Lisa Ostrin, SUNY College of Optometry, and Dr. Jay Neitz, University of Washington School of Medicine, who will participate in a session titled "Myopia Progression: Mechanisms & Management." The session will be moderated by Dr. Allen C. Ho, Wills Eye Hospital, Thomas Jefferson University, ARI Chair. Learn more and register on the ARI website, and visit Alcon at Booth #8001 in the ARVO Exhibition Hall. About Alcon. Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, Alcon offer the broadest portfolio of products to enhance sight and improve people's lives. Its Surgical and Vision Care products touch the lives of people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Its more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com. Media relations. Steven Smith + 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth) [email protected]
Tenpoint Therapeutics appoints Stephen S. Lane, MD, as Chief Medical Officer. Ophthalmology luminary and former Alcon CMO joins Tenpoint Therapeutics April 7, 2026 Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the appointment of Stephen S. Lane, MD, as Chief Medical Officer (CMO). In this role, Dr. Lane will join the executive team and oversee the company's clinical development strategy, medical affairs and pharmacovigilance. Dr. Lane brings significant ophthalmology leadership experience in clinical practice and the pharmaceutical industry, most recently serving as CMO and Head of Medical Safety at Alcon, Inc. He is recognized as a world-renowned ophthalmologist with more than 40 years of experience. Dr. Lane is the past President of the American Society of Cataract and Refractive Surgery (ASCRS), a former member of the Committee of Secretaries at the American Academy of Ophthalmology (AAO), a former Board Member and Officer of the International Society of Refractive Surgery (ISRS) and a Board Member of the Minnesota Academy of Ophthalmology. He has been honored with numerous awards, including the AAO Honor Award, Senior Achievement Award and Secretariat Award. "Dr. Lane is a highly respected ophthalmology leader whose experience spans clinical practice, product development and medical leadership at the highest levels of the industry," said Henric Bjarke, chief executive officer of Tenpoint Therapeutics. "He is exceptionally well suited to help drive Tenpoint Therapeutics as we advance innovative therapies for the aging eye and enter this next stage of commercial growth." Career highlights. Throughout his career, Dr. Lane has contributed extensively to clinical research and education, participating in more than 50 clinical trials, delivering over 400 lectures globally, presenting six domestic and international medical lectures and authoring numerous academic articles and book chapters. He also holds several biomedical patents. He currently serves as chief executive officer of the Holland Foundation for Sight Restoration, a nonprofit organization focused on establishing centers of excellence for ocular stem cell transplantation and advancing the education of corneal surgeons, and as a clinical professor of ophthalmology at the University of Minnesota. "I am excited to join Tenpoint Therapeutics at a time of significant opportunity for the Company and the field of ophthalmology," said Dr. Lane. "Tenpoint Therapeutics' dedication to advancing innovative treatments for the aging eye aligns closely with my passion for improving patient outcomes. I look forward to working with the team to further develop and deliver solutions that address the unmet needs of both patients and the eye care professionals who care for them." Dr. Lane earned his medical degree from the University of Minnesota, completed his ophthalmology residency at Pennsylvania State University and is fellowship-trained in cornea/external disease, anterior segment surgery and refractive surgery.
Alcon has launched Clareon TruPlus, an enhanced design monofocal and toric intraocular lens, at the American Society of Cataract and Refractive Surgery Annual Meeting in Washington, DC. The new IOL expands Alcon's Clareon portfolio, offering increased depth of focus whilst maintaining high-quality distance vision. According to bench data, TruPlus demonstrates a 3.5-letter improvement in simulated visual acuity at 66 centimetres compared to Clareon Monofocal, whilst offering higher distance image quality than competitor TECNIS Eyhance. The lens uses proprietary Opti-Balance Technology to extend depth of focus whilst maintaining distance image quality. TruPlus joins Alcon's broad IOL portfolio, which includes the leading monofocal lens, Vivity extended depth of focus IOL, and PanOptix trifocal IOL. The product will launch in additional markets later this year.